Clinical Trial Update: Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme [Phase 1, Phase 2]

View source ↗

Summary

A completed phase 1/2 trial evaluating BKM120 (buparlisib) in combination with bevacizumab for relapsed/refractory glioblastoma multiforme and other refractory …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• BKM120 (Buparlisib) (buparlisib)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-01-31